NASDAQ: TRDAEntrada Therapeutics Inc Stock
$8.94+0.07 (+0.79%)
Updated Apr 29, 2025
TRDA Price
$8.94
Fair Value Price
N/A
Market Cap
$336.10M
52 Week Low
$7.10
52 Week High
$21.79
P/E
5.08x
P/B
0.78x
P/S
3.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$210.78M
Earnings
$65.63M
Gross Margin
100%
Operating Margin
31.54%
Profit Margin
31.1%
Debt to Equity
0.23
Operating Cash Flow
-$42M
Beta
1.04
Next Earnings
Jun 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TRDA Overview
Entrada Therapeutics Incorporated is a biotechnology company developing Endosomal Escape Vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform is the base for a portfolio of oligonucleotide, antibody, and enzyme-based programs.The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne Muscular Dystrophy and Myotonic Dystrophy-Type 1. The company was known as CycloPorters Inc. until 2017. It was incorporated in 2016 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRDA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRDA
Ranked#130 of 462
Ranked#130 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important TRDA news, forecast changes, insider trades & much more!
TRDA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRDA is good value based on its earnings relative to its share price (5.08x), compared to the US market average (29.19x)
P/E vs Market Valuation
TRDA is good value based on its earnings relative to its share price (5.08x), compared to the US Biotechnology industry average (-158.75x)
P/E vs Industry Valuation
TRDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more TRDA due diligence checks available for Premium users.
Valuation
TRDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.08x
Industry
-158.75x
Market
29.19x
TRDA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TRDA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TRDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.78x
Industry
4.37x
TRDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRDA's financial health
Profit margin
Revenue
$37.4M
Net Income
$1.1M
Profit Margin
3%
TRDA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TRDA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$526.3M
Liabilities
$97.6M
Debt to equity
0.23
TRDA's short-term assets ($440.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRDA's short-term assets ($440.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.6M
Investing
$53.4M
Financing
$1.4M
TRDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRDA vs Biotech Stocks
Entrada Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.